Literature DB >> 23814432

Renal cortical necrosis in a renal transplant recipient.

M Eswarappa1, V Ravi, V Mysorekar.   

Abstract

Entities:  

Year:  2013        PMID: 23814432      PMCID: PMC3692159          DOI: 10.4103/0971-4065.111873

Source DB:  PubMed          Journal:  Indian J Nephrol        ISSN: 0971-4065


× No keyword cloud information.
  5 in total

1.  Significance of C4d deposition in antibody-mediated rejection.

Authors:  Asami Takeda; Yasuhiro Otsuka; Keiji Horike; Daijo Inaguma; Takahisa Hiramitsu; Takayuki Yamamoto; Koji Nanmoku; Norihiko Goto; Yoshihiko Watarai; Kazuharu Uchida; Kunio Morozumi; Takaaki Kobayashi
Journal:  Clin Transplant       Date:  2012-07       Impact factor: 2.863

2.  Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells.

Authors:  W Lieberthal; R Fuhro; C C Andry; H Rennke; V E Abernathy; J S Koh; R Valeri; J S Levine
Journal:  Am J Physiol Renal Physiol       Date:  2001-10

3.  Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.

Authors:  Hervé Sartelet; Olivier Toupance; Marianne Lorenzato; Fouad Fadel; Laure Hélène Noel; Eymeric Lagonotte; Philippe Birembaut; Jacques Chanard; Philippe Rieu
Journal:  Am J Transplant       Date:  2005-10       Impact factor: 8.086

4.  Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.

Authors:  Katja Keller; Christoph Daniel; Harald Schöcklmann; Karl-Hans Endlich; Dontscho Kerjaschki; Richard J Johnson; Christian Hugo
Journal:  Nephrol Dial Transplant       Date:  2006-07-20       Impact factor: 5.992

5.  The impact of C4d staining as a humoral injury marker.

Authors:  M Kara; F Demir; P Ata; L Ozel; G Gumrukcu; E Unal; M Canbakan; M Gucun; V Esadoglu; E Ozdemir; H Cemel; M I Titiz
Journal:  Transplant Proc       Date:  2012 Jul-Aug       Impact factor: 1.066

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.